VahatiCor Closes Oversubscribed Series B Financing to Accelerate A-FLUX® Development for Coronary Microvascular Dysfunction.

The new capital will advance the SERRA-I early feasibility study, engineering development, and preparation for additional studies on coronary microvascular dysfunction.

SANTA CLARA, Calif.--(BUSINESS WIRE)--VahatiCor, a medtech company transforming cardiac care for Coronary Microvascular Dysfunction (CMD), today announced the successful closing of its $23 million Series B financing led by S3 Ventures, with support from Intuitive Ventures, and a strategic investor. The capital will be deployed toward advancing SERRA-I enrollment, engineering development, and preparation for subsequent studies, including planning for pivotal trials and regulatory interactions.

“Securing this financing round from this esteemed group of investors is a significant validation of our therapy value proposition and the quality of our team,” said Marwan Berrada-Sounni, Co-Founder of VahatiCor. “VahatiCor can continue executing the critical next phase of our strategy to advance A-FLUX® through clinical studies and fulfill our mission of making this breakthrough therapy available to the millions suffering from Coronary Microvascular Dysfunction. We are proud and excited to work on an interventional treatment that aims to provide meaningful clinical benefit and symptom relief and improve the quality of life for millions of patients worldwide.”